Review
Open access
Aug 2026
Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis
RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes, but further research is needed to assess long-term efficacy and safety.
Muhammad Waqas Afzal, A. Haseeb, Ushna Ali et al.
· Medicine · 0 citations